PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

Biotech Day
CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm
Automated-Biopharmaceutical-Characterisation

Automated Biopharmaceutical Characterisation: From Early Development to Quality Control (QC)

The biophysical characterisation of biopharmaceuticals is critical to the development of a well-controlled large-scale production process. Moreover, as patents expire, the number of biosimilar candidates is rapidly rising, and the abbreviated development pathway associated with these molecules places a heightened emphasis on biophysical characterisation as a means to prove similarity. Guillaume Tremintin and Stuart Pengelley of Bruker Daltronics suggest that the complexity of a protein´s heterogeneity profile, compared to small molecules, demands a number of complementary techniques to achieve sufficient characterisation.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/Automated-biopharmaceutical-characterisation.pdf” width=”100%” height=”900px” style=”border:0;”]

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC